| Identification | Back Directory | [Name]
BAY 59-3074 | [CAS]
406205-74-1 | [Synonyms]
CS-2278
BAY 59-3074
BAY 59-3074;BAY-59-3074
BAY-59-3074; BAY 59-3074; BAY59-3074
3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl4,4,4-trifluoro-1-butanesulfonicacidester
1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl ester | [Molecular Formula]
C18H13F6NO4S | [MDL Number]
MFCD09027365 | [MOL File]
406205-74-1.mol | [Molecular Weight]
453.36 |
| Chemical Properties | Back Directory | [Boiling point ]
490.6±45.0 °C(Predicted) | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
DMSO:56.78(Max Conc. mg/mL);135.05(Max Conc. mM)
Ethanol:68.17(Max Conc. mg/mL);162.14(Max Conc. mM) | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bay 59-3074, is a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects. | [Definition]
ChEBI: 4,4,4-trifluoro-1-butanesulfonic acid is an aromatic ether. | [Biological Activity]
Novel CB 1 /CB 2 receptor partial agonist (K i values are 48.3 and 45.5 nM at human CB 1 and CB 2 receptors respectively). Orally active CB 1 agonist in vivo . Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain. |
|
|